Fish Adam, Knight Elizabeth, Henderson Katharine, Pollak Jeffrey, Schlachter Todd
Department of Interventional Radiology, Yale School of Medicine, New Haven, CT 06520, USA.
J Clin Med. 2024 Oct 13;13(20):6104. doi: 10.3390/jcm13206104.
To propose criteria for retreating previously embolized PAVMs and determining the effectiveness of the criteria to prevent paradoxical embolization. A retrospective review of patients with PAVMs treated at a single HHT center of excellence between 1 January 2013, and 10 September 2023, was performed. Patients with PAVM recurrence were either retreated or observed based on the following criteria for PAVM reintervention: 1. Embolic device(s) not creating a sufficiently dense matrix, such that a channel through them may be >/ 2 mm; 2. Accessory feeding artery or pulmonary collateral >/ 2 mm; 3. Hemoptysis in a patient with no other explanation. A total of 438 PAVMs were treated in 151 patients, including 106 patients with definite, 14 possible, and 31 doubtful HHT. Post-embolization PAVM recurrence occurred in 36 patients (36/151, 23.8%), including 15 patients (15/151, 9.9%) with 22 PAVMs (22/438, 5.0%) meeting criteria for reintervention. A total of 21 patients (21/151, 13.9%) with recurrence did not meet reintervention criteria and were therefore observed. Pre-treatment paradoxical embolization occurred in 36 patients (36/151) for a lifetime prevalence rate of 23.7%. Post-treatment paradoxical embolization did not occur in any patients following PAVM embolization (0/151). There was one case of iatrogenic paradoxical embolization in a patient being treated for systemic collateral reperfusion and hemoptysis. However, this was not included given that it was not a spontaneous event. Utilizing modern embolization techniques and devices, the proposed reintervention criteria, and screening intervals, paradoxical embolizations can be effectively prevented in patients with PAVMs.
提出对先前已栓塞的肺动静脉畸形(PAVM)进行再次治疗的标准,并确定这些标准预防反常栓塞的有效性。对2013年1月1日至2023年9月10日期间在一家卓越的遗传性出血性毛细血管扩张症(HHT)中心接受治疗的PAVM患者进行回顾性研究。根据以下PAVM再次干预标准,对PAVM复发的患者进行再次治疗或观察:1. 栓塞装置未形成足够致密的基质,使得通过它们的通道可能>/ 2毫米;2. 附属供血动脉或肺侧支>/ 2毫米;3. 无其他原因解释的咯血患者。151例患者共治疗438个PAVM,其中确诊HHT患者106例,可能HHT患者14例,可疑HHT患者31例。栓塞后PAVM复发36例(36/151,23.8%),其中15例(15/151,9.9%)的22个PAVM(22/438,5.0%)符合再次干预标准。共有21例(21/151,13.9%)复发患者不符合再次干预标准,因此进行观察。治疗前反常栓塞发生在36例患者(36/151)中,终生患病率为23.7%。PAVM栓塞后无患者发生治疗后反常栓塞(0/151)。有1例因系统性侧支再灌注和咯血接受治疗的患者发生医源性反常栓塞。然而,由于这不是自发事件,故未纳入。利用现代栓塞技术和装置、提议的再次干预标准和筛查间隔,可以有效预防PAVM患者的反常栓塞。